Belumosudil/KD-025 manufacturers
- Belumosudil mesylate
-
-
2025-12-19
- CAS:2109704-99-4
- Min. Order: 5kg
- Purity: 98%-102%
- Supply Ability: 200
- Belumosudil Mesylate
-
-
2025-12-16
- CAS:2109704-99-4
- Min. Order: 10mg
- Purity: 95%+
- Supply Ability: 10000000
|
| | Belumosudil/KD-025 Basic information |
| Product Name: | Belumosudil/KD-025 | | Synonyms: | Belumosudil mesylate (KD025 mesylate);KD025 mesylate;SLx-2119mesylate;2-(3-(4-((1H-indazol-5-yl)amino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide methanesulfonate;Phloroglucinol Impurity 212;Besylate Besylate;2-(3-(4-((1H-Indazol-5-yl)amino)-quinazolin-2-yl)phenoxy)-N-isopropyl-acetamide mesylate;Belumosudil mesylate | | CAS: | 2109704-99-4 | | MF: | C27H28N6O5S | | MW: | 548.62 | | EINECS: | | | Product Categories: | | | Mol File: | 2109704-99-4.mol |  |
| | Belumosudil/KD-025 Chemical Properties |
| form | Solid | | color | Light yellow to yellow | | InChIKey | ILQJXEIRBCHLOM-UHFFFAOYSA-N | | SMILES | S(O)(=O)(=O)C.N(C1=CC=C2NN=CC2=C1)C1=NC(C2C=CC=C(OCC(=O)NC(C)C)C=2)=NC2C=CC=CC1=2 |
| | Belumosudil/KD-025 Usage And Synthesis |
| Uses | Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties[1]. | | in vivo | Belumosudil (KD-025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. Belumosudil is at least as efficacious in aged, diabetic or female mice, as in normal adult males[2]. | | IC 50 | ROCK2: 105 nM (IC50); ROCK1: 24 μM (IC50) | | References | [1] Boerma, M., et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase. Blood Coagul Fibrinolysis. 2008 Oct;19(7):709-18. DOI:10.1097/MBC.0b013e32830b2891
[2] Lee, J.H., et al. Selective ROCK2 Inhibition In Focal Cerebral Ischemia. Ann Clin Transl Neurol. 2014 Jan 1;1(1):2-14. DOI:10.1002/acn3.19 |
| | Belumosudil/KD-025 Preparation Products And Raw materials |
|